Dr. Ripley Awarded NIH Grant to Study Mitochondrial Apoptosis Pathways
Media Component
Content
Dr. R. Taylor Ripley has received a $160,000 two-year R03 grant from the National Institute of Health for his project titled, "Dynamic BH3 Profiling with Patient Derived Organoids of Esophageal Cancer and Mesothelioma Enable Precision-Based Targeting of the Mitochondrial Apoptotic Pathway." The R03 Grant supports small research projects that can be carried out in a short period of time with limited resources.
Dr. Ripley is the director of the Mesothelioma Treatment Center. He is a nationally recognized, board-certified thoracic surgeon and expert in mesothelioma and thoracic surgical oncology. In addition to mesothelioma, he focuses on chest wall tumors, lung cancer, esophageal cancer, and thymoma / thymic carcinoma. For most tumors, Dr. Ripley specializes in robotic surgery to provide minimally invasive approaches to thoracic diseases. He also practices all facets of general thoracic surgery including infectious lung disease, benign esophageal diseases, and endoluminal interventions.
